Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

tecnimede - sildenafil - filmsko obložena tableta - sildenafil 50 mg / 1 tableta - sildenafil

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

tecnimede - sildenafil - filmsko obložena tableta - sildenafil 50 mg / 1 tableta - sildenafil

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

tecnimede - sildenafil - filmsko obložena tableta - sildenafil 50 mg / 1 tableta - sildenafil

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 60 mg / 1 tableta - dapoksetin

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 60 mg / 1 tableta - dapoksetin

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 30 mg / 1 tableta - dapoksetin

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

berlin-chemie ag - dapoksetin - filmsko obložena tableta - dapoksetin 30 mg / 1 tableta - dapoksetin

Uniunea Europeană - slovenă - EMA (European Medicines Agency)

pharmathen s.a. - clopidogrel (as besilate) - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - preprečevanje atherothrombotic eventsclopidogrel je navedeno v:izobraževanje odraslih bolnikih, ki trpijo za miokardni infarkt (od nekaj dni do manj kot 35 dni), ischaemic kap (od sedem dni, dokler ne manj kot za šest mesecev) ali sedež periferne arterijske bolezni;za odrasle bolnike, ki trpijo za akutni koronarni sindrom:non-st-segmenta,-dvig akutni koronarni sindrom (nestabilna angina pektoris ali ne-q-val, miokardni infarkt), vključno z bolniki, ki opravljajo stent umestitev po perkutani koronarni intervenciji, v kombinaciji z acetilsalicilne kisline (asa);st-segmenta,-dvig akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. preprečevanje atherothrombotic in thromboembolic dogodkov v atrijska fibrillationin odraslih bolnikov z atrijsko fibrilacijo, ki imajo vsaj en dejavnik tveganja za žilne dogodke, niso primerni za zdravljenje z vitaminom k antagonisti in ki imajo nizko tveganje krvavitve, clopidogrel je indiciran v kombinaciji s asa za preprečevanje atherothrombotic in thromboembolic dogodkov, vključno z možgansko kap.

Slovenia - slovenă - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

virbac 1ère avenue -

Uniunea Europeană - slovenă - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - okužbe z virusom hiv - antivirusi za sistemsko uporabo - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.